GPC3 and hepatocellular carcinoma: To examine whether activation of the ROS-p38 MAPK pathway was crucial to the downregulation of GPC3 expression by DSF, we examined GPC3 expression in EpCAM+ HCC cells co-treated with NAC or SB203580.